Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Alemtuzumab treatment in Denmark : A national study based on the Danish Multiple Sclerosis Registry. / Theodorsdottir, Asta; Debrabant, Birgit; Magyari, Melinda et al.

I: Multiple Sclerosis Journal, Bind 27, Nr. 14, 12.2021, s. 2254-2266.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Theodorsdottir, A, Debrabant, B, Magyari, M, Kant, M, Rasmussen, PV, Malmberg, CF, Norberg, IA, Hansen, V, Bech, D, Schmidt, MF, Schreiber, K, Frederiksen, JL, Sellebjerg, F & Illes, Z 2021, 'Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry', Multiple Sclerosis Journal, bind 27, nr. 14, s. 2254-2266. https://doi.org/10.1177/13524585211003291

APA

Theodorsdottir, A., Debrabant, B., Magyari, M., Kant, M., Rasmussen, P. V., Malmberg, C. F., Norberg, I. A., Hansen, V., Bech, D., Schmidt, M. F., Schreiber, K., Frederiksen, J. L., Sellebjerg, F., & Illes, Z. (2021). Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Multiple Sclerosis Journal, 27(14), 2254-2266. https://doi.org/10.1177/13524585211003291

CBE

Theodorsdottir A, Debrabant B, Magyari M, Kant M, Rasmussen PV, Malmberg CF, Norberg IA, Hansen V, Bech D, Schmidt MF, et al. 2021. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Multiple Sclerosis Journal. 27(14):2254-2266. https://doi.org/10.1177/13524585211003291

MLA

Vancouver

Theodorsdottir A, Debrabant B, Magyari M, Kant M, Rasmussen PV, Malmberg CF et al. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Multiple Sclerosis Journal. 2021 dec.;27(14):2254-2266. https://doi.org/10.1177/13524585211003291

Author

Theodorsdottir, Asta ; Debrabant, Birgit ; Magyari, Melinda et al. / Alemtuzumab treatment in Denmark : A national study based on the Danish Multiple Sclerosis Registry. I: Multiple Sclerosis Journal. 2021 ; Bind 27, Nr. 14. s. 2254-2266.

Bibtex

@article{9979e0f00060471087d0876284c62004,
title = "Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry",
abstract = "Objective: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark. Methods: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits. Results: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (p < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, p < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, p = 0.001). Conclusion: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.",
keywords = "adverse events, Alemtuzumab, CARE-MS, multiple sclerosis, observational study, real-world efficacy, registry",
author = "Asta Theodorsdottir and Birgit Debrabant and Melinda Magyari and Matthias Kant and Rasmussen, {Peter V.} and Malmberg, {Carl Fredrik} and Norberg, {Iver A.} and Victoria Hansen and Danny Bech and Schmidt, {Mathias F.} and Karen Schreiber and Frederiksen, {Jette L.} and Finn Sellebjerg and Zsolt Illes",
year = "2021",
month = dec,
doi = "10.1177/13524585211003291",
language = "English",
volume = "27",
pages = "2254--2266",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "14",

}

RIS

TY - JOUR

T1 - Alemtuzumab treatment in Denmark

T2 - A national study based on the Danish Multiple Sclerosis Registry

AU - Theodorsdottir, Asta

AU - Debrabant, Birgit

AU - Magyari, Melinda

AU - Kant, Matthias

AU - Rasmussen, Peter V.

AU - Malmberg, Carl Fredrik

AU - Norberg, Iver A.

AU - Hansen, Victoria

AU - Bech, Danny

AU - Schmidt, Mathias F.

AU - Schreiber, Karen

AU - Frederiksen, Jette L.

AU - Sellebjerg, Finn

AU - Illes, Zsolt

PY - 2021/12

Y1 - 2021/12

N2 - Objective: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark. Methods: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits. Results: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (p < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, p < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, p = 0.001). Conclusion: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.

AB - Objective: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark. Methods: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits. Results: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (p < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, p < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, p = 0.001). Conclusion: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.

KW - adverse events

KW - Alemtuzumab

KW - CARE-MS

KW - multiple sclerosis

KW - observational study

KW - real-world efficacy

KW - registry

UR - http://www.scopus.com/inward/record.url?scp=85103371082&partnerID=8YFLogxK

U2 - 10.1177/13524585211003291

DO - 10.1177/13524585211003291

M3 - Journal article

C2 - 33779361

AN - SCOPUS:85103371082

VL - 27

SP - 2254

EP - 2266

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 14

ER -